

Magnetic Peripheral Nerve Stimulation (mPNS)

Neuralace Medical

August 24, 2026

Goal of Today's Meeting

- We request that CMS update the payment for the Axon Therapy device and allow the additional nerve treatment to be paid separately (change indicator for 0767T from “N” to “S”)
- Currently, Axon Therapy (0766T and 0767T) is assigned to APC 5722 for \$220.60 in CY 2026.

***Suggested
option to
CMS:***

- Implement HOP 2025 recommendation to reassign Axon Therapy to APC 5724 (Level 4 Diagnostic and Related Services) for \$877.34 in CY 2026 and change status indicator of 0767T to “S”.


Axon Therapy Device is Unique Treatment That Provides Patients a Nonsurgical Option to Relieve Pain

- Magnetic peripheral nerve stimulator (mPNS) that delivers brief, focused, low-frequency magnetic pulses
- Simulates peripheral nerves to relieve chronic neuropathic pain
- Treatment protocol consists of 10 treatments, each lasting 13.3 minutes, delivered over a 3-month period, followed by monthly treatments
- Service performed by a physician or qualified healthcare professional who controls the stimulation intensity and area of effect based on detailed anatomical knowledge and patient interaction.



Axon Therapy is the Only Effective Option for Painful Diabetic Neuropathy After CMM and Before an Invasive Implantable Procedure

- Alternative device methods for treatment of diabetic neuropathy (ex. Spinal Cord Stimulation) can be expensive and carry risk
- VA has done over 10,000 treatments with Axon Therapy over the past 4 years with no adverse events



Generated with Vercel AI

Axon Therapy And Transcranial Magnetic Stimulation (TMS) Technical Characteristics Differ Significantly

- CMS stated that Axon Therapy device was comparable to CPT 90867, transcranial magnetic stimulation and assigned it to APC 5722

Different technical characteristics:

- Magnetic field settings
- Clinical Indications
- Target Area

Feature	Neuralace Medical Axon Therapy	NeuroStar TMS
	0.5 Hz – 2 Hz (Low Frequency)	10 Hz (High Frequency)
Type	mPNS (Magnetic Peripheral Nerve Stimulation)	rTMS (Repetitive Transcranial Magnetic Stimulation)
Target	Peripheral Nerves (Limbs/Body)	Brain (Central Nervous System)
Primary Use	Chronic Neuropathic Pain	Major Depressive Disorder (MDD)
Effect	Modulates nerves to reduce pain signals	Excites neurons to increase activity
Practitioner Effort	Active/Fine Tuning	Prescriptive

Additional Nerve is not an Add-On Process During the Therapy

In CY 2025 and 2026 OPPS,
CMS assigned 0767T with
status indicator “N”
(packaged)



Stimulation of an additional
nerve in a single session occurs in
approximately half of all patients,
it is not “always performed” and
should be eligible for payment if
0766T is reported



**Additional nerve stimulation
session involves complete
repositioning of the patient and
the coil, repeating the need for
properly mapping the nerve of
interest, evaluating paresthesia
and setting the device intensity**

**Neuralace has submitted to the American Medical
Association (AMA) to revise the code descriptors to help
further clarify the role of additional nerves in a session**

In Closing

- We request that CMS update the payment for the Axon Therapy device and allow the additional nerve treatment to be paid separately (change indicator for 0767T from “N” to “S”)
- Currently, Axon Therapy (0766T and 0767T) is assigned to APC 5722 for \$220.60 in CY 2026.

***Suggested
option to
CMS:***

- Implement HOP 2025 recommendation to reassign Axon Therapy to APC 5724 (Level 4 Diagnostic and Related Services) for \$877.34 in CY 2026 and change status indicator of 0767T to “S”.